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OBJECTIVE — Toinvestigatetheassociationbetweencirculatinglevelsofhepatocytegrowth
factor (HGF), a mesenchymal-derived pleiotrophic factor that is elevated in obesity, and the
prevalence of type 2 diabetes.
RESEARCH DESIGN AND METHODS — A cross-sectional analysis among 892 post-
menopausal women within the Women’s Health Initiative Observational Study (WHI-OS).
RESULTS — HGF levels positively correlated with BMI and homeostasis model assessment
for insulin resistance. In the multivariable analysis comparing the highest tertile with the lowest
tertileofHGF,theoddsratioforprevalentdiabeteswas2.47(95%CI[1.12–5.47],Pfortrend
0.014) after accounting for age, race, BMI, and other risk factors for diabetes.
CONCLUSIONS — HGF levels are associated with the presence of type 2 diabetes in post-
menopausal women. Future studies should consider the prospective evaluation of the associa-
tion of HGF with the development of type 2 diabetes.
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H
epatocyte growth factor (HGF) is a
mesenchymal-derived pleiotropic
factor that regulates growth, motil-
ity, and morphogenesis of various cells
(1). HGF is highly expressed in white ad-
ipose tissue (2,3), and it stimulates glu-
cose uptake in cultured adipocytes (4). In
humans, circulating HGF positively cor-
relates with insulin and glucose (5) and is
reported to be elevated in obesity (6),
metabolic syndrome (5), hypertension
(7), and coronary heart disease (8). Al-
though HGF levels are observed to be el-
evated in these diabetes-associated
conditions, the speciﬁc HGF-diabetes as-
sociation has not yet been investigated.
Hence, we conducted a study to examine
the cross-sectional relationship between
HGF and diabetes in a representative
sample of postmenopausal women (n 
892) within the Women’s Health Initia-
tive Observational Study (WHI-OS).
RESEARCH DESIGN AND
METHODS— The WHI-OS is an on-
going prospective study of 93,676 post-
menopausal women aged 50–79 years
(9). At baseline, the women were queried
about lifestyle factors, medical history,
andpersonalhabits,andaphysicalexam-
ination was performed to obtain height,
weight, and blood pressure. Fasting
blood samples were collected, centri-
fuged,frozenonsiteat70°C,andstored
in the specimen repository.
We conducted a study using data
from a case-cohort study within the
WHI-OS that aimed to evaluate the asso-
ciation of several adipokines and risk of
cancersofthebreast,colorectum,anden-
dometrium (10). The study population
for the current analysis included 892
women selected from the subcohort, a
representativesampleofWHI-OSwomen
without cancer at baseline. Diabetes was
deﬁned as a history of treated diabetes or
fasting glucose 126 mg/dl. Plasma HGF
levelsweremeasuredbyamultiplexassay
(Human Adipokine Panel B; Millipore,
Billerica, MA) based on Luminex xMAP
technology (http://www.luminexcorp.
com). The interassay coefﬁcient of varia-
tion for HGF assay was 11.7%. We
performed unconditional logistic regres-
sion analysis to evaluate the association
between HGF tertiles and prevalent dia-
betes while accounting for potential con-
founders.TestsoflineartrendacrossHGF
tertiles were conducted by assigning a
score for each tertile and including this
variable as a continuous variable in the
model. All statistical analyses were per-
formedusingSASversion9.1(Cary,NC),
and P values 0.05 were considered sta-
tistically signiﬁcant.
RESULTS— In this population, HGF
levels showed modest correlation with
age (r  0.20; P  0.0001), BMI (r 
0.18; P  0.0001), waist circumference
(r  0.19; P  0.0001), and insulin resis-
tance as measured by homeostasis model
assessment for insulin resistance (r 
0.21; P  0.0001). In addition, current
postmenopausal hormone use and alco-
hol intake were associated with lower
HGF levels (data not shown). In the age-
and race-adjusted logistic regression
model, the odds ratio (OR) for prevalent
diabetescomparingwomeninthehighest
tertile of HGF with those in the lowest
tertile was 3.63 (95% CI [1.83–7.19], P-
trend 0.0001), which was attenuated to
2.78 (1.36–5.69), P-trend  0.003 after
additional adjustment for BMI (Table 1).
This association remained signiﬁcant
when we further accounted for smoking,
physical activity, family history of diabe-
tes, alcohol intake, postmenopausal hor-
mone use, and plasma levels of C-reactive
protein (2.47 [1.12–5.47], P-trend 
0.014). To control for potential residual
confounding by adiposity, we evaluated
the effect of additional inclusion of waist
circumference in the model. The results,
however,weresimilar(2.34[1.04–5.28],
P-trend  0.024). Additional adjustment
for circulating insulin levels in the ﬁnal
multivariable model attenuated the re-
sults to borderline signiﬁcance (1.95
[0.87–4.40], P-trend  0.078). There
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tion by age, race, BMI, hormone use, or
C-reactive protein levels.
CONCLUSIONS — We found that
high HGF levels were associated with
prevalence of type 2 diabetes. HGF is a
mesenchymal-derived pleiotropic factor
that regulates growth, motility, and mor-
phogenesis of various cells (1). Although
HGF was known initially as a potent mi-
togenforhepatocytes,ithasrecentlybeen
shown to have effects on other cells, in-
cluding epithelial and endothelial cells. It
is expressed in several tissues including
lung, kidney, heart, brain, and especially
fat (11). Circulating levels of HGF are up
to threefold elevated in obese individuals,
demonstrate strong correlation with BMI
(r  0.68; P  0.0001), and substantially
decline following weight loss (2,6).
In addition to obesity, several studies
have linked HGF to other diabetes-
associated disease conditions. HGF levels
are elevated in patients with acute myo-
cardial infarction and predict mortality
following coronary intervention (8). Fur-
thermore, circulating HGF levels are also
associated with metabolic syndrome (5)
and hypertension (7), reinforcing the po-
tential role they may play in cardiometa-
bolic disease. We recently reported that
circulating HGF levels predicted the de-
velopment of ischemic stroke among
postmenopausal women in a large nested
case-control study within the WHI-OS
(12).
Alltheseobservationssupporttheno-
tion that HGF may also be involved in the
pathogenesis of diabetes. The biological
mechanisms linking HGF to the develop-
ment of diabetes, however, are not well
understood. It has been shown that HGF
is highly expressed in adipose tissue
where it exerts insulin-like effects and
stimulates glucose uptake by augmenting
the activity of phosphatidylinositol 3-ki-
nase–dependentproteinkinaseB(4).Itis
possible that obese individuals exhibit
HGF resistance, much like insulin resis-
tance, which then affects the efﬁciency of
glucosemetabolismandleadstoendothe-
lial dysfunction, a known risk factor for
diabetes. Alternatively, HGF may not be
directly associated with diabetes risk, but
it could be merely a bystander correlated
with or induced by diabetes risk factors.
CirculatingHGFlevelsmayriseinobesity
as a compensatory mechanism for the in-
creased insulin resistance. The elevated
HGFlevelsinobesitymaybesecondaryto
a fatty liver as reported in a study of pa-
tients with nonalcoholic steatohepatitis
(13); however, another study suggests
that the high HGF levels in obesity occur
even in the absence of any apparent liver
dysfunction (5). In our study, the HGF-
diabetes association was signiﬁcant even
after control of both BMI and waist circum-
ference, suggesting that it is independent of
obesity. The attenuation of the association
after controlling for insulin possibly sug-
gests that HGF may increase diabetes risk
by increasing insulin resistance. However,
only prospective studies can conﬁrm this
possibility.Ourstudyislimitedbyitscross-
sectional design, and we cannot determine
the cause and effect between HGF and dia-
betes. Additional studies, especially pro-
spective investigations, are warranted to
further explore the role of HGF in the de-
velopment of type 2 diabetes.
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